Table 1.
Phase | Cohorts | Investigational products | Number of Participants |
---|---|---|---|
Phase 2 (n = 200) | Safety Cohort (n = 200) | SII-NVX-CoV2373 | 150 |
Placebo | 50 | ||
Phase 3 (n = 1400) | Safety Cohort (n = 940) | SII-NVX-CoV2373 | 705 |
Control vaccine (NVX-CoV2373) | 235 | ||
Immunogenicity and Reactogenicity Cohort (n = 460) | SII-NVX-CoV2373 | 345 | |
Control vaccine (NVX-CoV2373) | 115 |